Search Results
Optimizing the treatment of transplant-eligible NDMM: using quadruplets in induction & consolidation
Analyzing isatuximab in quadruplet combinations in transplant-ineligible multiple myeloma
Addition of Isatuximab to RVd As Induction Therapy for Newly-Diagnosed, Transplant-Eligible MM Pts
Is there still a role in MM for auto-SCT after induction with a quadruplet combination?
The safety and efficacy of isatuximab, bortezomib, lenalidomide, and dexamethasone in NDMM
MUK Nine b update: Dara-CVRd induction plus dara-VRd consolidation for ultra-high risk NDMM and pPCL
An update on the RADAR trial: RCyBorD as induction therapy in newly diagnosed multiple myeloma
Changing Perspectives on Multiple Myeloma and ASCT
Addressing Current Questions and Controversies in the Management of Multiple Myeloma
Latest Advances in Multiple Myeloma a post ASH 2020 Summary
DEBATE: Which initial therapy for younger fit patients is best? - KRD and VRD
Daratumumab, Carfilzomib, Lenalidomide & Dexamethasone w/ MRD Res. Adapted Therapy in Newly Diag. MM
